Desnos-Ollivier Marie, Bretagne Stéphane, Raoux Dorothée, Hoinard Damien, Dromer Françoise, Dannaoui Eric
Institut Pasteur, Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS URA3012, 75724 Paris Cedex 15, France.
Antimicrob Agents Chemother. 2008 Sep;52(9):3092-8. doi: 10.1128/AAC.00088-08. Epub 2008 Jun 30.
Mutations in two specific regions of the Fks1 subunit of 1,3-beta-D-glucan synthase are known to confer decreased caspofungin susceptibility on Candida spp. Clinical isolates of Candida spp. (404 Candida albicans, 62 C. tropicalis, and 21 C. krusei isolates) sent to the French National Reference Center were prospectively screened for susceptibility to caspofungin in vitro by the broth microdilution reference method of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST). Twenty-eight isolates (25 C. albicans, 2 C. tropicalis, and 1 C. krusei isolate) for which the caspofungin MIC was above the MIC that inhibited 90% of the isolates of the corresponding species (MIC(90)) were subjected to molecular analysis in order to identify mutations in the fks1 gene. Substitutions in the deduced protein sequence of Fks1 were found for 8 isolates, and 20 isolates had the wild-type sequence. Among the six C. albicans isolates harboring mutations, six patterns were observed involving amino acid changes at positions 641, 645, 649, and 1358. For C. tropicalis, one isolate showed an L644W mutation, and for one C. krusei isolate, two mutations, L658W and L701M, were found. Two media, RPMI medium and AM3, were tested for their abilities to distinguish between isolates with wild-type Fks1 and those with mutant Fks1. In RPMI medium, caspofungin MICs ranged from 0.25 to 2 microg/ml for wild-type isolates and from 1 to 8 micro for mutant isolates. A sharper difference was observed in AM3: all wild-type isolates were inhibited by 0.25 micro of caspofungin, while caspofungin MICs for all mutant isolates were >or=0.5 microg/ml. These data demonstrate that clinical isolates of C. albicans, C. tropicalis, and C. krusei with decreased susceptibility to caspofungin in vitro have diverse mutations in the fks1 gene and that AM3 is potentially a better medium than RPMI for distinguishing between mutant and wild-type isolates using the AFST-EUCAST method.
已知1,3-β-D-葡聚糖合酶Fks1亚基两个特定区域的突变会使念珠菌属对卡泊芬净的敏感性降低。将送至法国国家参考中心的念珠菌属临床分离株(404株白色念珠菌、62株热带念珠菌和21株克鲁斯念珠菌分离株),采用欧洲抗生素敏感性测试委员会抗真菌药敏试验小组委员会(AFST-EUCAST)的肉汤微量稀释参考方法,对其进行卡泊芬净体外敏感性的前瞻性筛查。对28株卡泊芬净MIC高于抑制相应菌种90%分离株的MIC(MIC90)的分离株(25株白色念珠菌、2株热带念珠菌和1株克鲁斯念珠菌分离株)进行分子分析,以鉴定fks1基因中的突变。在8株分离株中发现了Fks1推导蛋白序列中的替代,20株分离株具有野生型序列。在6株携带突变的白色念珠菌分离株中,观察到6种模式,涉及641、645、649和1358位的氨基酸变化。对于热带念珠菌,1株分离株显示L644W突变,对于1株克鲁斯念珠菌分离株,发现了两种突变L658W和L701M。测试了两种培养基RPMI培养基和AM3区分具有野生型Fks1的分离株和具有突变型Fks1的分离株的能力。在RPMI培养基中,野生型分离株的卡泊芬净MIC范围为0.25至2μg/ml,突变型分离株的卡泊芬净MIC范围为1至8μg/ml。在AM3中观察到更明显的差异:所有野生型分离株均被0.25μg卡泊芬净抑制,而所有突变型分离株的卡泊芬净MIC≥0.5μg/ml。这些数据表明,体外对卡泊芬净敏感性降低的白色念珠菌、热带念珠菌和克鲁斯念珠菌临床分离株在fks1基因中有多种突变,并且使用AFST-EUCAST方法,AM3可能是比RPMI更好的区分突变型和野生型分离株的培养基。